P.62 INFLIXIMAB MODULATES MUCOSAL CYTOKINE PROFILE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Abstract

s / Digestive and Liver Disease 42S (2010) S61–S192 S125 was significantly reduced compared to non-inflamed areas, both in CD and UC patients, (CD: Median = 0.34, Q1-Q3 = 0.17-0.74, p=0.001; UC: Median = 0.47, Q1-Q3 = 0.24-0.77, p=0.0004), irrespective of the risk genotypes for the rs2631367 variant. The differences remained still significant when comparing the normalized quantities (CD: p=0.0001; UC: p=0.000056). Conclusions: The OCTN2 and IL23R mRNA levels are significantly reduced in inflamed colonic mucosa, in both CD and UC patients, irrespective of patients’ genotypes. # G. Inflammatory bowel diseases 1. Basic science